As a prognostic value of [18F]GE180 PET could be shown in recurrent glioma patients, a longitudinal analysis of individual patients would be of high interest to address changes of TSPO expression and their prognostic value: An ideal study should obtain serial [18F]GE180 PET imaging of a cohort of, e.g., IDH wild-type glioblastoma patients prior to initial resection, before and after radiochemotherapy, during and after adjuvant chemotherapy, and at the time of (suspected) recurrence. Here, TSPO is linked to central nervous system cancer.